PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.
Currently, prostate- specific antigen (PSA) is the most common oncological marker used for prostate cancer screening. However, high levels of PSA in benign prostatic hyperplasia and prostatitis decrease the specificity of PSA as a cancer marker. To increase the specificity of PSA, PSA derivatives and PSA kinetics have been used. However, these new techniques were not able to increase the diagnostic specificity for prostate cancer. Therefore, the search for new molecules and derivatives of PSA continues. With the aim of increasing the specificity of prostate cancer diagnosis, proPSA and the Prostate Health Index have been introduced. In this review, the roles of PSA, PSA derivatives, proPSA and the Prostate Health Index in Prostate Cancer diagnosis are examined.
Department of Biochemical, Ordu University Faculty of Medicine, Ordu, Turkey.
Sema Nur
SN
Ayyıldız
Department of Urology, Ordu University Faculty of Medicine, Ordu, Turkey.
Ali
A
Ayyıldız
PSA; Prostate cancer; proPSA; prostate health index